Replaces Prod. #: ALX-522-032
Biologically active CD137L (4-1BBL; TNFSF 9) comprising the whole extracellular tail domain (aa 49-93), which is important for the cross-linking of the protein that is essential for its biological activity.
Product Details
Alternative Name: | 4-1BBL, TNFSF 9 |
|
MW: | ~27kDa |
|
Source: | Produced in HEK 293 cells. The extracellular domain of human CD137L (aa 49-254) is fused at the N-terminus to a linker peptide (10 aa) and a FLAG®-tag. |
|
UniProt ID: | P41274 |
|
Concentration: | 0.1mg/ml after reconstitution. |
|
Formulation: | Lyophilized. Contains PBS, 5% trehhalose, and 5% mannitol. |
|
Purity: | ≥85% (SDS-PAGE) |
|
Endotoxin Content: | ≤1EU/µg purified protein (LAL test; Bio Whittaker). |
|
Specificity: | Binds to human CD137 (4-1BB). |
|
Reconstitution: | Reconstitute with 100µl sterile distilled water. Further dilutions should be made with medium containing 5% fetal calf serum. |
|
Shipping: | Blue Ice |
|
Long Term Storage: | -20°C |
|
Use/Stability: | Stable for at least 6 months after receipt when stored at -20°C. |
|
Handling: | Avoid freeze/thaw cycles. After reconstitution, prepare aliquots and store at -20°C. |
|
Scientific Background: | The CD137 ligand (CD137L, 4-1BBL) is a member of the tumor necrosis factor (TNF) family. CD137L is a type II, transmembrane protein found on activated macrophages, dendritic cells and mature B cells. The interaction with its receptor 4-1BB induces recruitment of TNF receptor-associated factor 1 (TRAF1) and TRAF2 and interaction with the kinase p56lck. CD137 and CD137L have been reported to be involved in tumor rejection, apoptosis, anti-viral immunity, diabetes, in T and B cell co-stimulation and modulation of the immune response. |
|
Technical Info/Product Notes: | FLAG is a registered trademark of Sigma-Aldrich Co. |
|
Regulatory Status: | RUO - Research Use Only |
|
Figure: Dose-dependent binding of recombinant human soluble CD137L to CD137:Fc (human). Recombinant human CD137L saturates its receptor at a concentration range of 2-4’000ng/ml.
Method: Receptor binding assay: a 96-well ELISA plate was coated O/N with 50ng per well of CD137 (human):Fc (human) (rec.) (4-1BB:Fc) (Prod. No.
ALX-522-031). After a blocking step, the indicated concentrations of rhsCD137L were added for 1 hour. After extensive washing, Enhancer for Ligands (Prod. No.
ALX-804-034) was added for 1 hour. Bound ligand was revealed by a rabbit anti-mouse IgG-HRP (1:1’000 dilution, Jackson Immunoresearch) incubated for 1 hour. OPD (Sigma) was used as a substrate and absorbance was measured at 490nm in an ELISA reader."
Please mouse over
Product Literature References
Production of recombinant human trimeric CD137L (4-1BBL). Cross-linking is essential to its T cell co-stimulation activity: C. Rabu, et al.; J. Biol. Chem.
280, 41472 (2005),
Abstract;
Full Text